Dr. McGann is a physician-researcher and Director of the newly combined (Pediatric and Adult) Lifespan Sickle Cell Program of Rhode Island. Dr. McGann is board certified in Pediatrics and Pediatric Hematology/Oncology. Dr. McGann is an international leader in both clinical care and research for individuals with sickle cell disease. His research is focused on improving outcomes for individuals with sickle cell disease living both here in the United States and globally. Dr. McGann has research funding from the National Institutes of Health (NIH), the Doris Duke Charitable Foundation, and the American Society of Hematology. He is an active member of the American Academy of Pediatrics, the American Society of Hematology, the American Society of Pediatric Hematology/Oncology, and the Global Sickle Cell Disease Network.
Dr. McGann is a fierce advocate for health equity, particularly related to the care of individuals with sickle cell disease. A focus of the newly developing Lifespan Comprehensive Sickle Cell Center is to develop an anti-racist, patient-centered approach throughout the entire hospital system to facilitate the equitable care of patients throughout our healthcare system.
| Weyand, Angela C, McGann, Patrick T, Sholzberg, Michelle. "Sex specific definitions of anaemia contribute to health inequity and sociomedical injustice." The Lancet Haematology, vol. 9, no. 1, 2022, pp. e6-e8. |
| Boucher, Alexander A., Bedel, Ashley, Jones, Sommer, Lenahan, Stephanie F., Geer, Rebecca, McGann, Patrick T. "A retrospective study of the safety and efficacy of low molecular weight iron dextran for children with iron deficiency anemia." Pediatric Blood & Cancer, vol. 68, no. 7, 2021. |
| Karkoska, Kristine A., Haber, Kenneth, Elam, Megan, Strong, Sarah, McGann, Patrick T. "Academic Challenges and School Service Utilization in Children with Sickle Cell Disease." The Journal of Pediatrics, vol. 230, 2021, pp. 182-190. |
| Sadaf, Alina, Seu, Katie G., Thaman, Elizabeth, Fessler, Rose, Konstantinidis, Diamantis G., Bonar, Holly A., Korpik, Jennifer, Ware, Russell E., McGann, Patrick T., Quinn, Charles T., Kalfa, Theodosia A. "Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell Anemia." Frontiers in Physiology, vol. 12, 2021. |
| Quinn, Charles T., Niss, Omar, Dong, Min, Pfeiffer, Amanda, Korpik, Jennifer, Reynaud, Mary, Bonar, Holly, Kalfa, Theodosia A., Smart, Luke R., Malik, Punam, Ware, Russell E., Vinks, Alexander A., McGann, Patrick T. "Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics‐guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia." British Journal of Haematology, vol. 194, no. 3, 2021, pp. 617-625. |
| Weyand, Angela C, McGann, Patrick T. "Eliminating race-based reference ranges in haematology: a call to action." The Lancet Haematology, vol. 8, no. 6, 2021, pp. e462-e466. |
| Karkoska, Kristine, McGann, Patrick T. "How I approach disease‐modifying therapy in children with sickle cell disease in an era of novel therapies." Pediatric Blood & Cancer, vol. 68, no. 12, 2021. |
| Karkoska, Kristine, Quinn, Charles T., Niss, Omar, Pfeiffer, Amanda, Dong, Min, Vinks, Alexander A., McGann, Patrick T. "Hydroyxurea improves cerebral oxygen saturation in children with sickle cell anemia." American Journal of Hematology, vol. 96, no. 5, 2021, pp. 538-544. |
| Karkoska, Kristine, Todd, Kevin, Niss, Omar, Clapp, Kelly, Fenchel, Lynette, Kalfa, Theodosia A., Malik, Punam, Quinn, Charles T., Ware, Russell E., McGann, Patrick T. "Implementation of near‐universal hydroxyurea uptake among children with sickle cell anemia: A single‐center experience." Pediatric Blood & Cancer, vol. 68, no. 6, 2021. |
| Sadaf, Alina, Quinn, Charles T., Korpik, Jennifer B., Pfeiffer, Amanda, Reynaud, Mary, Niss, Omar, Malik, Punam, Ware, Russell E., Kalfa, Theodosia A., McGann, Patrick T. "Rapid and automated quantitation of dense red blood cells: A robust biomarker of hydroxyurea treatment response." Blood Cells, Molecules, and Diseases, vol. 90, 2021, pp. 102576. |
| Dexter, Daniel, McGann, Patrick T. "Saving lives through early diagnosis: the promise and role of point of care testing for sickle cell disease." British Journal of Haematology, vol. 196, no. 1, 2021, pp. 63-69. |
| Vistica Sampino, Emily, McGann, Patrick T. "System's failure: Poor adherence to guidelines for children with sickle cell disease." Pediatric Blood & Cancer, vol. 69, no. 2, 2021. |
| Perez-Plazola, Marina S., Tyburski, Erika A., Smart, Luke R., Howard, Thad A., Pfeiffer, Amanda, Ware, Russell E., Lam, Wilbur A., McGann, Patrick T. "AnemoCheck-LRS: an optimized, color-based point-of-care test to identify severe anemia in limited-resource settings." BMC Medicine, vol. 18, no. 1, 2020. |
| Dong, Min, McGann, Patrick T. "Changing the Clinical Paradigm of Hydroxyurea Treatment for Sickle Cell Anemia Through Precision Medicine." Clinical Pharmacology & Therapeutics, vol. 109, no. 1, 2020, pp. 73-81. |
| Meier, Emily R., Creary, Susan E., Heeney, Matthew M., Dong, Min, Appiah-Kubi, Abena O., Nelson, Stephen C., Niss, Omar, Piccone, Connie, Quarmyne, Maa-Ohui, Quinn, Charles T., Saving, Kay L., Scott, John P., Talati, Ravi, Latham, Teresa S., Pfeiffer, Amanda, Shook, Lisa M., Vinks, Alexander A., Lane, Adam, McGann, Patrick T. "Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia." Trials, vol. 21, no. 1, 2020. |
| Karkoska, Kristine, Quinn, Charles T., Clapp, Kelly, McGann, Patrick T. "Severe infusion‐related reaction to crizanlizumab in an adolescent with sickle cell disease." American Journal of Hematology, vol. 95, no. 12, 2020. |
| Vawter-Lee, Marissa, McGann, Patrick T. "The Increasing Global Burden of Childhood Disability: A Call for Action." Pediatrics, vol. 146, no. 1, 2020. |
| Power-Hays, Alexandra, McGann, Patrick T. "When Actions Speak Louder Than Words — Racism and Sickle Cell Disease." New England Journal of Medicine, vol. 383, no. 20, 2020, pp. 1902-1903. |
| Farrell, Ann T., Panepinto, Julie, Desai, Ankit A., Kassim, Adetola A., Lebensburger, Jeffrey, Walters, Mark C., Bauer, Daniel E., Blaylark, Rae M., DiMichele, Donna M., Gladwin, Mark T., Green, Nancy S., Hassell, Kathryn, Kato, Gregory J., Klings, Elizabeth S., Kohn, Donald B., Krishnamurti, Lakshmanan, Little, Jane, Makani, Julie, Malik, Punam, McGann, Patrick T., Minniti, Caterina, Morris, Claudia R., Odame, Isaac, Oneal, Patricia Ann, Setse, Rosanna, Sharma, Poornima, Shenoy, Shalini. "End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings." Blood Advances, vol. 3, no. 23, 2019, pp. 4002-4020. |
| Tshilolo, Léon, Tomlinson, George, Williams, Thomas N., Santos, Brígida, Olupot-Olupot, Peter, Lane, Adam, Aygun, Banu, Stuber, Susan E., Latham, Teresa S., McGann, Patrick T., Ware, Russell E. "Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa." New England Journal of Medicine, vol. 380, no. 2, 2019, pp. 121-131. |
| Ware, Russell E., McGann, Patrick T., Quinn, Charles T. "Hydroxyurea for children with sickle cell anemia: Prescribe it early and often." Pediatric Blood & Cancer, vol. 66, no. 8, 2019. |
| Gurunathan, Arun, Tarango, Cristina, McGann, Patrick T., Niss, Omar, Quinn, Charles T. "Non–transfusion-dependent β-Thalassemia Because of a Single β-Thalassemia Mutation and Coinherited α-Globin Gene Triplication: Need for Increased Awareness to Prevent Incorrect and Delayed Diagnosis." Journal of Pediatric Hematology/Oncology, vol. 42, no. 6, 2019, pp. e494-e496. |
| McGann, Patrick T., Niss, Omar, Dong, Min, Marahatta, Anu, Howard, Thad A., Mizuno, Tomoyuki, Lane, Adam, Kalfa, Theodosia A., Malik, Punam, Quinn, Charles T., Ware, Russell E., Vinks, Alexander A. "Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia." American Journal of Hematology, vol. 94, no. 8, 2019, pp. 871-879. |
| Risinger, Mary, Christakopoulos, Georgios E., Schultz, Corinna L., McGann, Patrick T., Zhang, Wenying, Kalfa, Theodosia A. "Hereditary elliptocytosis-associated alpha-spectrin mutation p.L155dup as a modifier of sickle cell disease severity." Pediatric Blood & Cancer, vol. 66, no. 2, 2018, pp. e27531. |
| Dong, Min, McGann, Patrick T., Mizuno, Tomoyuki, Ware, Russell E., Vinks, Alexander A. "Model-based dosing with concentration feedback as an integral part of personalized hydroxycarbamide management." British Journal of Clinical Pharmacology, vol. 84, no. 7, 2018, pp. 1410-1412. |
| McGann, Patrick T., Williams, Anne M., Ellis, Graham, McElhinney, Kathryn E., Romano, Laurel, Woodall, Julia, Howard, Thad A., Tegha, Gerald, Krysiak, Robert, Lark, R. Murray, Ander, E. Louise, Mapango, Carine, Ataga, Kenneth I., Gopal, Satish, Key, Nigel S., Ware, Russell E., Suchdev, Parminder S. "Prevalence of inherited blood disorders and associations with malaria and anemia in Malawian children." Blood Advances, vol. 2, no. 21, 2018, pp. 3035-3044. |
| McGann, Patrick T., Williams, Thomas N., Olupot-Olupot, Peter, Tomlinson, George A., Lane, Adam, Luís Reis da Fonseca, José, Kitenge, Robert, Mochamah, George, Wabwire, Ham, Stuber, Susan, Howard, Thad A., McElhinney, Kathryn, Aygun, Banu, Latham, Teresa, Santos, Brígida, Tshilolo, Léon, Ware, Russell E., None, None. "Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa." American Journal of Hematology, vol. 93, no. 4, 2018, pp. 537-545. |
| Gladding, Sophia P., McGann, Patrick T., Summer, Andrea, Russ, Christiana M., Uwemedimo, Omolara T., Matamoros Aguilar, Martha, Chakraborty, Rana, Moore, Molly, Lieh-Lai, Mary, Opoka, Robert, Howard, Cynthia, John, Chandy C., None, None. "The Collaborative Role of North American Departments of Pediatrics in Global Child Health." Pediatrics, vol. 142, no. 1, 2018. |
| Boucher, Alexander A., Pfeiffer, Amanda, Bedel, Ashley, Young, Jennifer, McGann, Patrick T. "Utilization trends and safety of intravenous iron replacement in pediatric specialty care: A large retrospective cohort study." Pediatric Blood & Cancer, vol. 65, no. 6, 2018, pp. e26995. |
| Smart, Luke R., Ambrose, Emmanuela E., Raphael, Kevin C., Hokororo, Adolfine, Kamugisha, Erasmus, Tyburski, Erika A., Lam, Wilbur A., Ware, Russell E., McGann, Patrick T. "Simultaneous point-of-care detection of anemia and sickle cell disease in Tanzania: the RAPID study." Annals of Hematology, vol. 97, no. 2, 2017, pp. 239-246. |
| McGann, Patrick T., Hoppe, Carolyn. "The pressing need for point-of-care diagnostics for sickle cell disease: A review of current and future technologies." Blood Cells, Molecules, and Diseases, vol. 67, 2017, pp. 104-113. |
| Dong, Min, McGann, Patrick T., Mizuno, Tomoyuki, Ware, Russell E., Vinks, Alexander A. "Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia." British Journal of Clinical Pharmacology, vol. 81, no. 4, 2016, pp. 742-752. |
| Niss, Omar, Chonat, Satheesh, Dagaonkar, Neha, Almansoori, Marya O., Kerr, Karol, Rogers, Zora R., McGann, Patrick T., Quarmyne, Maa-Ohui, Risinger, Mary, Zhang, Kejian, Kalfa, Theodosia A. "Genotype-phenotype correlations in hereditary elliptocytosis and hereditary pyropoikilocytosis." Blood Cells, Molecules, and Diseases, vol. 61, 2016, pp. 4-9. |
| McGann, Patrick T. "Time to Invest in Sickle Cell Anemia as a Global Health Priority." Pediatrics, vol. 137, no. 6, 2016. |
| McGann, Patrick T., Grosse, Scott D., Santos, Brigida, de Oliveira, Vysolela, Bernardino, Luis, Kassebaum, Nicholas J., Ware, Russell E., Airewele, Gladstone E. "A Cost-Effectiveness Analysis of a Pilot Neonatal Screening Program for Sickle Cell Anemia in the Republic of Angola." The Journal of Pediatrics, vol. 167, no. 6, 2015, pp. 1314-1319. |
| McGann, Patrick T., Tyburski, Erika A., de Oliveira, Vysolela, Santos, Brigida, Ware, Russell E., Lam, Wilbur A. "An accurate and inexpensive color-based assay for detecting severe anemia in a limited-resource setting." American Journal of Hematology, vol. 90, no. 12, 2015, pp. 1122-1127. |
| McGann, Patrick T., Schaefer, Beverly A., Paniagua, Mary, Howard, Thad A., Ware, Russell E. "Characteristics of a rapid, point-of-care lateral flow immunoassay for the diagnosis of sickle cell disease." American Journal of Hematology, vol. 91, no. 2, 2015, pp. 205-210. |
| McGann, Patrick T., Tshilolo, Léon, Santos, Brigida, Tomlinson, George A., Stuber, Susan, Latham, Teresa, Aygun, Banu, Obaro, Stephen K., Olupot‐Olupot, Peter, Williams, Thomas N., Odame, Isaac, Ware, Russell E., None, None. "Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub‐Saharan Africa: Rationale and Design of the REACH Trial." Pediatric Blood & Cancer, vol. 63, no. 1, 2015, pp. 98-104. |
| McGann, Patrick T, Ware, Russell E. "Hydroxyurea therapy for sickle cell anemia." Expert Opinion on Drug Safety, vol. 14, no. 11, 2015, pp. 1749-1758. |
| McGann, Patrick T. "Sickle Cell Anemia: An Underappreciated and Unaddressed Contributor to Global Childhood Mortality." The Journal of Pediatrics, vol. 165, no. 1, 2014, pp. 18-22. |
| McGann, Patrick T., Ferris, Margaret G., Ramamurthy, Uma, Santos, Brigida, Oliveira, Vysolela, Bernardino, Luis, Ware, Russell E. "A prospective newborn screening and treatment program for sickle cell anemia in Luanda, Angola." American Journal of Hematology, vol. 88, no. 12, 2013, pp. 984-989. |
| McGann, P. T., Nero, A. C., Ware, R. E. "Current Management of Sickle Cell Anemia." Cold Spring Harbor Perspectives in Medicine, vol. 3, no. 8, 2013, pp. a011817-a011817. |
| Despotovic, Jenny M., McGann, Patrick T., Smeltzer, Matthew, Aygun, Banu, Ware, Russell E. "RHD zygosity predicts degree of platelet response to anti-D immune globulin treatment in children with immune thrombocytopenia." Pediatric Blood & Cancer, vol. 60, no. 9, 2013, pp. E106-E108. |
| McGann, Patrick T., Despotovic, Jenny M., Howard, Thad A., Ware, Russell E. "A novel laboratory technique demonstrating the influences of RHD zygosity and the RhCcEe phenotype on erythrocyte D antigen expression." American Journal of Hematology, vol. 87, no. 3, 2011, pp. 266-271. |
| McGann, Patrick T., Flanagan, Jonathan M., Howard, Thad A., Dertinger, Stephen D., He, Jin, Kulharya, Anita S., Thompson, Bruce W., Ware, Russell E., None, None. "Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: Results from the BABY-HUG phase III clinical trial." Pediatric Blood & Cancer, vol. 59, no. 2, 2011, pp. 254-257. |
Dr. McGann has been involved in global health research since 2011, primarily in the Republic of Angola, where he lived from 2011 to 2013 to develop and implement a newborn screening program for sickle cell disease. His current global health work is focused on evaluating and implementing point-of-care diagnostics for sickle cell disease and other hematologic conditions and working to improve the use of hydroyxurea therapy in low-resource settings. Notably, the NIH-funded Promoting the Utilization and Safety of Hydroyxurea Using Precision (PUSH-UP) in Africa aims to investigate the optimal dosing and monitoring strategy for children with sickle cell disease in Angola to allow for improved and more widespread use of hydroxyurea throughout sub-Saharan Africa.
Dr. McGann's US-based work has focused on optimizing the use of hydroxyurea using individualized, pharmacokinetics guided dosing for children with sickle cell disease. This work, supported by a K23 Award from the NIH/NHLBI led to formal training in pharmacology, through which Dr. McGann will complete his PhD degree in 2022. This work has led to subsequent research funded by the Doris Duke Charitable Foundation (Hydroxyurea Optimization through Precision Study, HOPS, NCT03789591), the American Society of Hematology, and the National Institutes of Health.
Current:
NIH/NHLBI (U01HL157872)
Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa
Role: Principal Investigator
Dates: 2021-2026
Direct Costs: $1,731,330
Summary: The PUSHUP study will compare weight-based dosing of hydroxyurea to individualized, pharmacokinetics-guided dosing for children with sickle cell anemia in Angola. An important second aim will evaluate the safety of limited laboratory monitoring with hydroxyurea therapy to expand the use of hydroyxurea in low-resource settings, where laboratory monitoring may not be available.
NIH/NICHD (R21HD107675)
Developmental Pharmacology of Hydroxyurea Across the Age Span for the Treatment of Sickle Cell Anemia
Role: Principal Investigator (Multi-PI)
Dates: 2022-2024
Direct Costs: $300,000
Summary: This study will evaluate the pharmacokinetics, pharmacodynamics, and pharmacogenomics of hydroxyurea for individuals with hydroxyurea from infancy through adulthood and aims to better understand how the dosing and effects of hydroxyurea change with age.
Doris Duke Charitable Foundation (#2017090)
Maximizing Fetal Hemoglobin Responses to Hydroxyurea Using Precision Medicine
Role: Principal Investigator
Dates: 2017-2023
Direct Costs: $990,000
Summary: The Hydroxyurea Optimization through Precision Study (HOPS) is a multicenter, randomized trial comparing weight-based dosing of hydroxyurea to individualized, pharmacokinetics-guided dosing for children with sickle cell anemia. The study is ongoing at 14 pediatric sickle cell centers in the United States and aims to complete enrollment in 2022.
American Society of Hematology (ASH) Scholar Award
Hydroxyurea Pharmacokinetics for Adults with Sickle Cell Anemia
Role: Principal Investigator
Dates: 2020-2022
Direct Costs: $150,000
Summary: This study will investigate the impact of renal function, bone marrow reserve, in combination with pharmacokinetic and pharmacodynamic parameters in an effort to create an individualized, pharmacokinetics-guided dosing strategy for adults with sickle cell disease.
Completed
NIH/NHLBI (K23HL128885)
Therapeutic Response Evaluation and Adherence Trial (TREAT): A Prospective Study of Hydroxyurea for Children with Sickle Cell Anemia
Role: Principal Investigator
Dates: 2015-2021
Direct Costs: $910,194
Summary: The TREAT study developed and prospectively evaluated the feasibility, safety and clinical benefits of an individualized dosing strategy of hydroxyurea for children with sickle cell anemia. Through the Career Development aspect of this K23 Award, Dr. McGann is to obtain his PhD in Molecular, Cellular, and Biochemical Pharmacology from the University of Cincinnati, expected in 2022.
Thrasher Research Fund Early Career Award
Determination of Pneumococcal Serotypes Among Angolan Children with Invasive Pneumococcal Disease
Role: Principal Investigator
Dates: 2012-2013
| Year | Degree | Institution |
|---|---|---|
| 2022 | PhD | University of Cincinnati |
| 2013 | MS | Baylor College of Medicine |
| 2006 | MD | Tufts University |
| 2002 | BA | College of the Holy Cross |
| Fellowship | Texas Children's Hospital, Pediatric Hematology/Oncology | 2011-2012 | |
| Fellowship | St. Jude Children's Research Hospital, Pediatric Hematology/Oncology | 2009-2011 | |
| Internship and Residency | MassGeneral Hospital for Children, Pediatrics | 2006-2009 |
NIH Loan Repayment Program Awardee, 2014-2022
Chair, American Academy of Pediatrics Section on Global Health (2018-2022)
American Society of Hematology (ASH) Scholar Award, 2020
Thrasher Research Fund Early Career Award, 2012
| Name | Title |
|---|---|
| Bailey, Jeffrey | Mencoff Family Associate Professor of Translational Research, Associate Professor of Pathology and Laboratory Medicine |
| D'Angelo, Christina | Assistant Professor of Psychiatry and Human Behavior, Clinician Educator |
| Leroy-Melamed, Maayan | Assistant Professor of Pediatrics, Clinician Educator |
| Wilson, Taneisha | Assistant Professor of Emergency Medicine |
| Medical License | State of Rhode Island | 2021- | #MD17928 |
| Board Certification | American Board of Pediatrics, Pediatric Hematology/Oncology | 2013- | #2646 |
| Board Certification | American Board of Pediatrics, Pediatrics | 2009- | #95351 |
| Director, Lifespan Comprehensive Sickle Cell Center. Hasbro Children's Hospital & Rhode Island Hospital, 2021- |
